Online inquiry

IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4810MR)

This product GTTS-WQ4810MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets DPP4 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001379604.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1803
UniProt ID P27487
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4810MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ959MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ11479MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ4052MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ4771MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ11688MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ13319MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ15243MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ14400MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW